Riluzole likely lacks antidepressant efficacy in ketamine non-responders

Journal of Psychiatric Research

Volumn 58, Issue , 2014, Pages 197-199

  Niciu, Mark J ^a   Luckenbaugh, David A ^a   Ionescu, Dawn F ^a   Richards, EricaM ^a   Vande Voort, Jennifer L ^a   Ballard, Elizabeth D ^a   Brutsche, Nancy E ^a   Furey, Maura L ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Glutamate; Ketamine; Major depressive disorder; Riluzole; Treatment resistant depression

Indexed keywords

KETAMINE; RILUZOLE; AMINO ACID RECEPTOR BLOCKING AGENT;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; DRUG EFFICACY; HUMAN; LETTER; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; SUICIDAL IDEATION; TREATMENT RESISTANT DEPRESSION; ADULT; CONTROLLED STUDY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE RESPONSE; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KETAMINE; MALE; MIDDLE AGED; RILUZOLE; TREATMENT OUTCOME;

EID: 84912574194     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.07.022     Document Type: Letter

References (10)

1. Banasr M., Chowdhury G.M., Terwilliger R., Newton S.S., Duman R.S., Behar K.L., et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010, 15:501-511.
2. Ibrahim L., Diazgranados N., Franco-Chaves J., Brutsche N., Henter I.D., Kronstein P., et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012, 37:1526-1533.
3. Mathew S.J., Murrough J.W., aan het Rot M., Collins K.A., Reich D.L., Charney D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010, 13:71-82.
4. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
5. Niciu M.J., Henter I.D., Luckenbaugh D.A., Zarate C.A., Charney D.S. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol 2014, 54:119-139.
6. Niciu M.J., Kelmendi B., Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav 2012, 100:656-664.
7. Sanacora G., Kendell S.F., Levin Y., Simen A.A., Fenton L.R., Coric V., et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007, 61:822-825.
8. Shelton R.C., Osuntokun O., Heinloth A.N., Corya S.A. Therapeutic options for treatment-resistant depression. CNS Drugs 2010, 24:131-161.
9. Zarate C.A., Payne J.L., Quiroz J., Sporn J., Denicoff K.K., Luckenbaugh D., et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004, 161:171-174.
10. Zarate C.A., Quiroz J.A., Singh J.B., Denicoff K.D., De Jesus G., Luckenbaugh D.A., et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005, 57:430-432.